A second Trump presidency could be a boost for biomedical innovation, but it also risks eroding public trust in the pharmaceutical industry if science, trade and public health are sidelined. +Get the most important news from Switzerland in your inbox Big pharmaceutical companies including the two big Swiss players, Roche and Novartis, had a lot at stake in the US presidential election. Under the Biden administration, the US government started to negotiate down drug prices with industry for the first time. A second Trump presidency throws this and many other Biden-era healthcare policies up in the air. “We still have to see what Trump’s polices actually are,” David Reddy, who heads the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), told SWI swissinfo.ch on the sidelines of the FT Global Pharma and Biotech Summit in London. “Regardless of political party though, everyone wants the same thing – good health and innovation.” How Trump plans to move ...
